Is Procept Biorobotics Corp (PRCT) overvalued? · rev $224.5M
Procept Biorobotics Corp (PRCT) is a medical devices company listed on US.
This page asks whether Procept Biorobotics Corp (PRCT) looks expensive on cached numbers — not a short thesis.
Latest reported PRCT revenue for 2024-12-31 was $224.5M. Net income was -$91.4M. Revenue was up 64.8% from 2023-12-31 to 2024-12-31. PRCT currently screens at market cap $1.52B.
PRCT currently screens at market cap $1.52B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PRCT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PRCT stock page for the full model, not this heading.
Not investment advice.